I&I News

Sanofi (NASDAQ: SNY) has been identified as one of the most undervalued foreign stocks according to analysts, with a forward P/E ratio of 10.04 and a potential upside of 25.16%. Berenberg Bank recently reiterated a Buy rating with a price target of $62. However, UBS downgraded Sanofi from Buy to Neutral, lowering its price target from €105 to €88, citing recent clinical trial failures, particularly the failure of Tolebrutinib in treating progressive multiple sclerosis and a delayed FDA approval due to serious liver injury risks. UBS analysts expressed concerns over Sanofi's weak pipeline and suggested that mergers and acquisitions may be the only viable option for the company moving forward. The downgrade also included an 8% reduction in mid-term earnings estimates for 2027-2030.

Read full article: https://www.insidermonkey.com/blog/10-most-undervalued-foreign-stocks-to-buy-according-to-analysts-2-1680667/2/

Subscribe to our real-time email alerts: https://www.stellarint.ai/Services/

LEO Pharma A/S announced the presentation of 23 scientific posters at the Maui Derm Hawaii 2026 conference, focusing on advancements in medical dermatology. The posters will cover various skin conditions, including atopic dermatitis (AD), chronic hand eczema (CHE), generalized pustular psoriasis (GPP), and pyoderma gangrenosum (PG). Key data include analyses of patient-reported outcomes and long-term results for treatments such as ADBRY® (tralokinumab-ldrm) and ANZUPGO® (delgocitinib) cream, as well as a post-marketing study on SPEVIGO® (spesolimab-sbzo). The presentations aim to enhance understanding of these conditions and the impact of treatments on patients' quality of life. LEO Pharma emphasizes its commitment to improving dermatological care through ongoing research and innovation in chronic skin diseases.

Read full article: https://finance.yahoo.com/news/leo-pharma-presents-twenty-three-140000477.html

Subscribe to our real-time email alerts: https://www.stellarint.ai/Services/

The National Institute for Health and Care Excellence (NICE) has approved Roche's Gazyvaro (obinutuzumab) for use in the NHS in England and Wales, specifically for treating lupus nephritis, a kidney condition associated with systemic lupus erythematosus (SLE). This decision allows approximately 12,000 patients with kidney damage from lupus to access the drug, which is administered as an intravenous infusion twice a year after an initial treatment phase. Clinical trials indicated that 46% of patients treated with Gazyvaro achieved normal or near-normal kidney function, compared to 33% with the existing treatment mycophenolate mofetil (MMF) alone. Gazyvaro's approval follows its label extension for lupus nephritis last year, and it has also shown efficacy in broader SLE cases. The drug's introduction is anticipated to improve the quality of life for patients suffering from lupus nephritis, which significantly impacts their daily lives and mental health. Roche reported $728 million in Gazyvaro sales in the first nine months of 2025, with projections suggesting potential annual sales could reach $1.7 billion by the end of the decade.

Read full article: https://pharmaphorum.com/news/nice-backs-roche-lupus-drug-supports-kidney-function

Subscribe to our real-time email alerts: https://www.stellarint.ai/Services/

Halozyme Therapeutics Inc. (NASDAQ: HALO) has been ghlighted as one of the best mid-cap growth stocks to buy, with 42 hedge fund holders. TD Cowen recently raised its price target on the company from $79 to $90, maintaining a Buy rating ahead of Q4 2025 earnings. A significant development for Halozyme is its global collaboration with Takeda, which grants Takeda exclusive access to Halozyme's ENHANZE drug-delivery technology for vedolizumab, a biologic therapy for ulcerative colitis and Crohn's disease. This partnership aims to enhance treatment flexibility and reduce therapy management time for patients. Halozyme specializes in researching, developing, and commercializing proprietary enzymes and devices both in the US and internationally.

Read full article: https://www.insidermonkey.com/blog/14-best-mid-cap-growth-stocks-to-buy-right-now-1677287/8/

Subscribe to our real-time email alerts: https://www.stellarint.ai/Services/

Clarivate's annual report ghlights 11 gh-impact drugs expected to make significant sales by 2031, focusing on therapies for obesity, diabetes, rare diseases, cancer, and women's health. Notable mentions include Lilly's orforglipron, projected to generate $11.1 billion in obesity sales and $5.2 billion for type 2 diabetes, and retatrutide, expected to reach $30.1 billion combined. Other drugs include GSK's Exdensur for severe asthma, Johnson & Johnson's icotrokinra for plaque psoriasis, and Otsuka's Voyxact for immunoglobulin A nephropathy. The report also discusses Sanofi's tolebrutinib for multiple sclerosis, BeOne Medicines' BGB-16673 for chronic lymphocytic leukaemia, and Bristol Myers Squibb's mezigdomide for multiple myeloma. Additionally, it covers Johnson & Johnson's Inlexzo for bladder cancer and Corcept Therapeutics' relacorilant for ovarian cancer. The report emphasizes the potential of these drugs to address unmet medical needs and their expected market impact.

Read full article: https://pharmaphorum.com/news/11-high-impact-drugs-look-out-2026

Subscribe to our real-time email alerts: https://www.stellarint.ai/Services/

Crystalys Therapeutics, a clinical-stage biopharmaceutical company focused on gout treatment, has appointed Justin Thacker as Chief Financial Officer to support the advancement of its Phase 3 trials for dotinurad. Thacker brings over 25 years of finance leadership experience, particularly in the life sciences sector, and has previously held CFO positions at various biopharma organizations. s appointment comes as the company initiates its Phase 3 trials, RUBY and TOPAZ, for dotinurad, which is a next-generation oral URAT1 inhibitor aimed at reducing uric acid levels and gout symptoms. Dotinurad has already received regulatory approval in several Asian countries and is being advanced toward global regulatory approval and commercial launch.

Read full article: https://www.prnewswire.com/news-releases/crystalys-therapeutics-expands-leadership-team-with-appointment-of-justin-thacker-as-chief-financial-officer-to-support-advancement-of-phase-3-trials-of-dotinurad-302665997.html

Subscribe to our real-time email alerts: https://www.stellarint.ai/Services/

AB Science SA has received a patent from the Japanese Patent Office for the use of its lead compound, masitinib, in treating progressive forms of multiple sclerosis (MS) until 2041. This patent marks the first protection granted for masitinib in this indication. Masitinib is a first-in-class oral tyrosine kinase inhibitor that targets both mast cells and microglia, showing a significant reduction in disability progression in patients with primary progressive MS (PPMS) and non-active secondary progressive MS (nSPMS) based on positive results from clinical studies. The company is pursuing similar patent protections for masitinib in other conditions, including amyotrophic lateral sclerosis and Alzheimer’s disease. The need for effective treatments for progressive MS is gh, as current therapies primarily target relapsing forms of the disease, leaving a significant gap in treatment options for progressive cases.

Read full article: https://www.globenewswire.com/news-release/2026/01/21/3223115/0/en/AB-Science-receives-Japanese-patent-protection-for-the-use-of-masitinib-in-progressive-forms-of-multiple-sclerosis-MS-until-2041.html

Subscribe to our real-time email alerts: https://www.stellarint.ai/Services/

Soligenix (NASDAQ: SNGX) has announced positive top-line results from its Phase 2 clinical trial of SGX945, an investigational therapy for treating aphthous ulcers associated with Behcet's disease, a rare inflammatory condition characterized by unpredictable flare-ups and periods of remission. Current treatments for Behcet's disease, which can lead to painful ulcers and systemic complications, are limited and often inconsistent. The trial results represent a significant advancement in addressing the needs of patients suffering from this challenging condition, as Behcet's disease is classified as a variable vessel vasculitis affecting blood vessels throughout the body.

Read full article: https://www.digitaljournal.com/pr/news/investorbrandnetwork/soligenix-nasdaq-sngx-announces-positive-1577436650.html

Subscribe to our real-time email alerts: https://www.stellarint.ai/Services/

Can-Fite BioPharma Ltd. has completed patient enrollment for its Phase 2a clinical trial of Namodenoson, a drug being tested for advanced pancreatic adenocarcinoma. The trial, which is multicenter and open-label, focuses on evaluating the safety, clinical activity, and pharmacokinetics of Namodenoson in patients whose disease has progressed after prior therapy. Participants are administered 25 mg of Namodenoson twice daily in 28-day cycles, and the drug has shown a favorable safety profile thus far. The study is led by Prof. Salomon Stemmer at the Davidoff Center in Israel, with top-line efficacy data expected in Q3 2026. Namodenoson, an A3 adenosine receptor agonist, has also received Orphan Drug Designation from the FDA for pancreatic cancer and is being evaluated for other cancers, including liver cancer. Can-Fite is a clinical-stage biotechnology company focused on developing drugs for cancer and inflammatory diseases.

Read full article: https://www.biospace.com/press-releases/can-fite-completes-patient-enrollment-in-phase-2a-pancreatic-cancer-study-of-namodenoson

Subscribe to our real-time email alerts: https://www.stellarint.ai/Services/

Corvus Pharmaceuticals, Inc. (CRVS) experienced a ~66% increase in premarket trading after announcing plans to begin a mid-stage trial for its lead asset, soquelitinib, aimed at treating atopic dermatitis (eczema). This decision follows positive results from earlier-stage trials, indicating potential for the drug's effectiveness in managing the skin condition.

Read full article: https://seekingalpha.com/news/4540443-corvus-lead-drug-moves-mid-stage-eczema-trial

Subscribe to our real-time email alerts: https://www.stellarint.ai/Services/

Akeso, Inc. announced that its supplemental New Drug Application (sNDA) for gumokimab, an anti-IL-17A monoclonal antibody, has been accepted for review by the National Medical Products Administration (NMPA) in China for the treatment of active ankylosing spondylitis (AS). This marks the second indication for gumokimab, following its previous acceptance for moderate-to-severe psoriasis. The NDA acceptance is based on positive results from a pivotal Phase III clinical trial, which demonstrated significant improvements in AS symptoms and quality of life for patients. Akeso is advancing its non-oncology drug candidates and has a robust pipeline of over 50 innovative assets, with several already commercially available. The company aims to provide innovative biological medicines and has developed a comprehensive drug development platform.

Read full article: https://www.prnewswire.com/news-releases/akeso-announces-nmpa-acceptance-of-second-nda-for-gumokimab-il-17a-inhibitor-in-active-ankylosing-spondylitis-302664371.html

Subscribe to our real-time email alerts: https://www.stellarint.ai/Services/

The article provides a recap of rheumatology news and updates for the fourth quarter of 2025, authored by Victoria Johnson and published on January 8, 2026. It ghlights significant developments in the field, including the approval of a new biosimilar for the U.S. market.

Read full article: https://www.rheum-live.com/view/new-ra-biosimilar-approved-for-u-s-market

Subscribe to our real-time email alerts: https://www.stellarint.ai/Services/

SpyGlass Pharma and AgomAb Therapeutics have announced their initial public offerings (IPOs) as they aim to become publicly traded companies on the Nasdaq. SpyGlass, which is further along in clinical development, is working on a bimatoprost drug for ocular hypertension and open-angle glaucoma, currently in Phase III trials. AgomAb is focused on AGMB-129, a treatment for fibrostenosing Crohn's disease, which is in Phase IIa trials. Both companies plan to use the funds raised from their IPOs to support their clinical trials and potential product launches. SpyGlass will trade under the symbol SGP, while AgomAb will use AGMB.

Read full article: https://www.biospace.com/business/2026-ipo-train-keeps-chugging-as-agomab-spyglass-eye-nasdaq-debut

Subscribe to our real-time email alerts: https://www.stellarint.ai/Services/

Henry Gosebruch has been appointed as the new CEO of Galapagos, tasked with revitalizing the company after years of setbacks, including clinical failures and leadership changes. With approximately $3.5 billion in capital, Gosebruch aims to explore new opportunities beyond the company's previous focus on cell therapy, which has been officially wound down due to gh costs and lack of viable partnerships. He plans to consider a broader range of therapeutic areas, particularly in immunology and solid tumors, while maintaining strong ties with Gilead, a major investor. Gosebruch's approach emphasizes patience in finding the right opportunities rather than rushing into decisions, as the company restructures its workforce to about 35-40 employees following recent layoffs.

Read full article: https://www.biospace.com/business/jpm26-galapagos-new-ceo-is-here-to-finally-turn-the-ship-around

Subscribe to our real-time email alerts: https://www.stellarint.ai/Services/